Sukses Main Mahjong Ways Best808 Pahami Scatter dan Kombinasinya Mahjong Ways Best808 Simbol Scatter Meningkatkan Peluang Menang Kesalahan Umum Pemain Mahjong Ways di Best808 Auto Jackpot Strategi Terbaik Fitur Scatter Mahjong Ways Best808 Mahjong Ways Best808 Panduan Scatter Wild Hasil Maksimal Pola Mahjong Ways Best808 Gacor Scatter Menang Bongkar Misteri Mahjong Ways Best808 Kunci Kemenanganmu Mau Cuan Maksimal di Mahjong Ways Best808 Trik Menggunakan Scatter Agar Lebih Untung Main Mahjong Ways di Best808 Kenali Pola Scatter Free Spin Gandakan Kemenanganmu Rahasia Scatter Mahjong Ways Best808 Strategi Jitu Menang Jackpot Besar Misteri Scatter Mahjong Ways Tol777 Kunci Jackpot Besar Bongkar Rahasia Mahjong Ways Tol777 Fitur Scatter Pola Menang Mahjong Ways Tol777 Simbol Scatter Kemenangan Besar Main Mahjong Ways di Tol777 Cara Memanfaatkan Scatter Strategi Mahjong Ways Tol777 Rahasia Scatter Trik Menang Jackpot Analisis Pola Permainan Mahjong Ways Keunggulan Mahjong Ways Tol777 vs Tradisional Kombinasi Simbol Tertinggi Mahjong Ways Langkah Meningkatkan Keahlian Mahjong Ways Mahjong Ways Tol777 Berbeda dari Permainan Mengapa Mahjong Ways Tol777 Diminati Dunia Optimalkan Putaran Mahjong Ways Tol777 Sejarah Mahjong Ways Tol777 dan Keunikan Simbol Mahjong Ways Tol777 dan Pemanfaatannya Strategi Lanjutan Mahjong Ways Tol777 Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Live RTP Dan Kasino Online Cara Cepat Kuasai Mahjong Ways Tol777 Mengapa Mahjong Ways Tol777 Populer Mitos & Fakta Mahjong Ways Tol777 Strategi Pemula vs Pro Mahjong Ways Teknik Profesional Mahjong Ways Tol777 Mahjong Ways Tol777: Keberuntungan atau Skill? Mahjong Ways Tol777: Tradisi dan Inovasi Panduan Mahjong Ways Tol777 untuk Pemula Rahasia Menang Mahjong Ways Tol777 Tips Efektif Main Mahjong Ways Tol777 Kasino Online Kasino Online Kasino Online Kasino Online Kasino Online Kasino Online Kasino Online Kasino Online Kasino Online Kasino Online main mahjong ways di malam hari jackpot profit mengamati permainan mahjong ways dengan baik dan benar merasa bosan pada malam hari? coba cara bermain mahjong ways ini minum kopi memotivasi bermain mahjong ways nelayan tebing tinggi pola mahjong ways hasil mencengangkan pelajar bandung download mahjong ways peluang besar trik dan pola mahjong ways pemuda belanda tato mahjong ways mengenang jackpot satu miliar pola rtp mahjong ways terbaik resep bermain mahjong ways dengan mudah slot mahjong ways dikenal sejak abad ke-11 hingga zaman milenial video mahjong ways viral menghebohkan warga indonesia warga jayamakmur dulu diremehkan, bermain mahjong ways hidup berlimpah harta unik keren bali cendera mata mahjong ways rp100000 warga bingung merek cat dinding sama mahjong ways

COVID-19 Reminds Us That Both Innovation and Affordability Are Needed

In her March 25 Forbes editorial, Sally Pipes documented how the private sector is rising to the health challenges of the coronavirus. Whether it is Moderna launching clinical trials for a COVID-19 vaccine or Gilead Sciences investigating whether one of its medicines, Remdesivir, is effective against the coronavirus, private sector firms are innovating at lightning speed. These efforts exemplify the broader societal benefits created by an innovative pharmaceutical industry.

The second installment in PRI’s Center for Medical Economics Escape the Drug Pricing Maze video series explains that in order to foster innovation, the prices of cutting-edge medicines must be temporarily high in order to cover the capital costs for developing them. And, this process works.

Not only does the current system incent the development of vaccines and treatments for coronavirus, the strong incentive to innovate has also led to cures for spinal muscular atrophy and hepatitis C. Recent innovations have also led to more effective treatments for cancer and auto-immune diseases. This progress would have been impossible without the positive incentives created by the U.S. pharmaceutical market.

Innovation isn’t the only important goal, however. As the third installment in the Escape the Drug Pricing Maze video series explains, widespread affordability is also crucial. Here too, the U.S. pharmaceutical market excels – although not without some important flaws that must be fixed.

Starting with the good news, 90 percent of the traditional medicines that patients purchase at the pharmacy counter are low-cost generic medicines. The vast majority of these (over 95 percent) cost $20 or less. So, most of the times when a patient receives a prescription from their doctor, that prescription will be affordable.

But, there are exceptions.

First, even if each individual prescription is affordable, as people age they will typically take a large number of prescriptions. When added together, people’s total prescription costs are unaffordable even though the cost for each individual prescription is affordable. Michael Mandel of the Progressive Policy Institute termed this problem the prescription escalator.

Second, the top 5 medicines account for more than 10 percent of total drug spending, and the top 50 accounted for 40 percent of total drug spending. Patients who require one of these medicines will face excessive costs, especially if their out of pocket costs are not capped.

Third, there are cracks in the system that inflicts excessive costs on patients. For example, the overly complex (and opaque) pricing system distorts the costs and transfers an excessive amount of a drug’s cost on patients – particularly patients that lack health insurance.

It is imperative to fix these problems, but not at the expense of the broad-based affordability that has already been achieved, nor the innovative manufacturers searching for tomorrow’s cures. These fixes require effective out-of-pocket caps, reforms to promote competition in the innovative high-cost biologics market (e.g. promote biosimilars), and pricing reform that transition the distribution system to a net-price model.

Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.

Scroll to Top